Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 2, 2007, Pages 203-209

  Lockhart, A C ^a   Bukowski, R ^b   Rothenberg, M L ^a   Wang, K K ^c   Cooper, W ^a   Grover, J ^c   Appleman, L ^d   Mayer, P R ^c   Shapiro, M ^c   Zhu, A X ^d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c PFIZER INC   (United States)

^d DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

Clinical trial; Docetaxel; MAC 321; Paclitaxel; Phase I

Indexed keywords

MAC 321; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; KIDNEY FUNCTION; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NEUROPATHY; PRIORITY JOURNAL; PROSTATE CARCINOMA; SMALL CELL CARCINOMA; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEVER; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PACLITAXEL; TREATMENT OUTCOME;

EID: 34248335926     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0362-y     Document Type: Article

References (24)

1. Brahmer JR, Shapiro M, Carducci K, Beers S, Cameron B, Cohen M, Rubin EH (2003) Phase I trial of a potent novel taxane, TL00139 (MAC-321), in patients with advanced malignant solid tumors. Proc Am Soc Clin Oncol 22 (abstr 527)
2. Burris HA (1996) Optimal use of docetaxel (Taxotere): maximizing its potential. Anticancer Drugs 7(Suppl 2):25-28
3. Campling BG, Young LC, Baer KA, Lam YM, Deeley RG, Cole SP, Gerlach JH (1997) Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res 3:115-122
4. Camps C, Felip E, Sanchez JM, Massuti B, Artal A, Paz-Ares L, Carrato A, Alberola V, Blasco A, Baselga J, Astier L, Voi M, Rosell R, Spanish Lung Cancer G (2005) Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol 16:597-601
5. Dumontet C, Sikic BI (1999) Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17:1061-1070
6. Gelmon KA, Latreille J, Tolcher A, Genier L, Fisher B, Forand D, D'Aloisio S, Vernillet L, Daigneault L, Lebecq A, Besenval M, Eisenhauer E (2000) Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol 18:4098-4108
7. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, Fojo T (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 97:2904-2909
8. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615-627
9. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58
10. Horwitz SB (1992) Mechanism of action of taxol. Trends Pharmacol Sci 13:134-136
11. Investigational Drug Brochure (2002) MAC-321 - WAY-179321 (TL 00139)
12. Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, Poruchynsky MS, Steinberg SM, Mannan N, Fojo T, Swain SM (2005) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23:2726-2734
13. Moos PJ, Fitzpatrick FA (1998) Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits. Cell Growth Differ 9:687-697
14. Moos PJ, Fitzpatrick FA (1998) Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 95:3896-3901
15. Ogretmen B, Bahadori HR, McCauley MD, Boylan A, Green MR, Safa AR (1998) Co-ordinated over-expression of the MRP and gamma-glutamylcysteine synthetase genes, but not MDR1, correlates with doxorubicin resistance in human malignant mesothelioma cell lines. Int J Cancer 75:757-761
16. Okuno S, Maples WJ, Mahoney MR, Fitch T, Stewart J, Fracasso PM, Kraut M, Ettinger DS, Dawkins F, Erlichman C (2005) Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium. J Clin Oncol 23:3069-3073
17. Ramnath N, Hamm J, Schwartz G, Holden S, Eckhardt SG, Vredenburg MR, Bernacki RJ, Lathia C, Kanter P, Creaven PJ (2004) A phase I pharmacokinetic study of BAY59: a novel taxane. Oncology 67:123-129
18. Rodi DJ, Janes RW, Sanganee HJ, Holton RA, Wallace BA, Makowski L (1999) Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. J Mol Biol 285:197-203
19. Rosier RN, O'Keefe RJ, Teot LA, Fox EJ, Nester TA, Puzas JE, Reynolds PR, Hicks DG (1997) P-glycoprotein expression in cartilaginous tumors. J Surg Oncol 65:95-105
20. Rowinsky EK, Tolcher AW (2001) Antimicrotubule agents. In: Devita J, Hellman VTS, Rosenberg SA (eds) Cancer principles and practice, 6th edn. Lippincott Williams and Wilkins, Philadelphia, PA, pp 431-452
21. Rowinsky EK (1997) Paclitaxel pharmacology and other tumor types. Semin Oncol 24:S19-11-S19-12
22. Sampath D, Discafani CM, Loganzo F, Beyer C, Liu H, Tan X, Musto S, Annable T, Gallagher P, Rios C, Greenberger LM (2003) MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol Cancer Ther 2:873-884
23. van Brussel JP, Mickisch GH (2003) Multidrug resistance in prostate cancer. Onkologie 26:175-181
24. Wolff AC, Donehower RC, Carducci MK, Carducci MA, Brahmer JR, Zabelina Y, Bradley MO, Anthony FH, Swindell CS, Witman PA, Webb NL, Baker SD (2003) Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 9:3589-3597